Nerviano Medical Sciences: MOU signed with Chinese society GUIZHOU YIBAI Pharmaceutical Co Ltd. for the licensing of the molecule nemorubicin
Nerviano, June 7, 2010
part of the work of the Forum on Cooperation between Chinese and Italian SMEs, the center of cancer research Nerviano Medical Sciences (NMS) has signed today with the company Guizhou Yibai Pharmaceutical Co., Ltd of Beijing, a Memorandum of Understanding (MOU) for granting an exclusive license for the Chinese market, the rights to development and exploitation of an anticancer molecule.
Signatories to the Agreement, Baielli Luciano, CEO of NMS and Mrs. Quiling Dou, Chairman of the Chinese group.
Guizhou Yibai Pharmaceutical Co., Ltd is a Shanghai-listed pharmaceutical company, active in the development, production and marketing of drugs in modern medicine and pharmaceutical chemicals, particularly relating to five categories: cancer, cardiovascular, antibronchiali, antipyretic and anti-viral . The active antitumor
"nemorubicin" third-generation anthracycline, for the treatment of carcinoma of the liver, which has a particularly high in China, has reached the level of development of Phase 2 in Europe and the United States.
After the recent success (including the agreement reached with Pfizer last week, the contract-ROL Oncology Network Lombarda and redesigning the organizational structure) today's agreement is further confirmation of the new way of revitalizing the Centre, the flagship of the Italian drug discovery.
The agreement stipulates, in line with the characteristics of the sector, three types of license revenues (Upfronts / milestones / royalties) that, effective from the year already ongoing and growing the next three years, reaching maximum economic expression with the marketing of the drug on the Chinese market.
0 comments:
Post a Comment